Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2015

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Review, H1 2015', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10

Therapeutics Development 11

Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Overview 11

Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Comparative Analysis 12

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics under Development by Companies 13

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics under Investigation by Universities/Institutes 15

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Products under Development by Companies 20

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Products under Investigation by Universities/Institutes 23

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Companies Involved in Therapeutics Development 24

AstraZeneca PLC 24

Athersys, Inc. 25

Bayer AG 26

Betagenon AB 27

Cardiolynx AG 28

CardioVascular BioTherapeutics, Inc. 29

Celgene Corporation 30

Diffusion Pharmaceuticals LLC 31

DNAVEC Corporation 32

KunWha Pharmaceutical Co., Ltd. 33

MedImmune, LLC 34

miRagen Therapeutics, Inc. 35

Multi Gene Vascular Systems Ltd 36

Nuo Therapeutics, Inc. 37

Proteon Therapeutics, Inc. 38

Recardio GmbH 39

RegenoCELL Therapeutics, Inc. 40

Resverlogix Corp. 41

Sagene Pharmaceuticals, Inc. 42

Stemedica Cell Technologies, Inc. 43

Theravasc, Inc. 44

ViroMed Co., Ltd. 45

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(cilostazol + organic nitrate) ER-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

AEM-28-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ALD-301-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Annexin A-5-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

CVBT-141C-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

DVC1-0101-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

ELS-140-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

MEDI-6012-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Mesenchymal Stem Cells-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

MGN-6114-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

MultiGeneAngio-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MultiGeneGraft-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

MultiStem-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

O-304-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

PDA-002-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

REC-03-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

rivaroxaban-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

RVX-208-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

sarpogrelate SR-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

selegiline + Antiplatelet Drugs-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

sodium nitrite SR-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

SYN-20112312RU-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

ticagrelor-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

transcrocetinate sodium-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

TXA-127-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

VM-202-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

vonapanitase-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Recent Pipeline Updates 105

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects 144

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Discontinued Products 148

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Product Development Milestones 149

Featured News & Press Releases 149

Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 149

Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 149

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 150

Jul 09, 2014: Development Of Russian Innovative Drug For Peripheral Arterial Disease Is Supported By The Council Of Maryland Biotech Companies (USA) 151

Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 152

Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 154

Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 154

Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 156

Jul 17, 2012: AstraZeneca To Initiate New Study Of BRILINTA In Patients With Peripheral Artery Disease 156

Nov 15, 2010: Diffusion Achieves Positive Results In Phase I/II Clinical Trial Of Trans Sodium Crocetinate In Peripheral Artery Disease 157

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2015 11

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Comparative Analysis by Unknown Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Development by Companies, H1 2015 (Contd..2) 22

Products under Investigation by Universities/Institutes, H1 2015 23

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by AstraZeneca PLC, H1 2015 24

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Athersys, Inc., H1 2015 25

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Bayer AG, H1 2015 26

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Betagenon AB, H1 2015 27

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Cardiolynx AG, H1 2015 28

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 29

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Celgene Corporation, H1 2015 30

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Diffusion Pharmaceuticals LLC, H1 2015 31

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by DNAVEC Corporation, H1 2015 32

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by KunWha Pharmaceutical Co., Ltd., H1 2015 33

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by MedImmune, LLC, H1 2015 34

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by miRagen Therapeutics, Inc., H1 2015 35

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 36

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Nuo Therapeutics, Inc., H1 2015 37

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Proteon Therapeutics, Inc., H1 2015 38

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Recardio GmbH, H1 2015 39

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by RegenoCELL Therapeutics, Inc., H1 2015 40

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Resverlogix Corp., H1 2015 41

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 42

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 43

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by Theravasc, Inc., H1 2015 44

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Pipeline by ViroMed Co., Ltd., H1 2015 45

Assessment by Monotherapy Products, H1 2015 46

Assessment by Combination Products, H1 2015 47

Number of Products by Stage and Target, H1 2015 49

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics-Recent Pipeline Updates, H1 2015 105

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects, H1 2015 144

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects (Contd..1), H1 2015 145

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects (Contd..2), H1 2015 146

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Dormant Projects (Contd..3), H1 2015 147

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Discontinued Products, H1 2015 148

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2015 11

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Comparative Analysis by Unknown Stage Development, H1 2015 19

Assessment by Monotherapy Products, H1 2015 46

Number of Products by Top 10 Targets, H1 2015 48

Number of Products by Stage and Top 10 Targets, H1 2015 48

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AstraZeneca PLC

Athersys, Inc.

Bayer AG

Betagenon AB

Cardiolynx AG

CardioVascular BioTherapeutics, Inc.

Celgene Corporation

Diffusion Pharmaceuticals LLC

DNAVEC Corporation

KunWha Pharmaceutical Co., Ltd.

MedImmune, LLC

miRagen Therapeutics, Inc.

Multi Gene Vascular Systems Ltd

Nuo Therapeutics, Inc.

Proteon Therapeutics, Inc.

Recardio GmbH

RegenoCELL Therapeutics, Inc.

Resverlogix Corp.

Sagene Pharmaceuticals, Inc.

Stemedica Cell Technologies, Inc.

Theravasc, Inc.

ViroMed Co., Ltd.

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutic Products under Development, Key Players in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Overview, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com